US 10,646,565 B2Granted

Treatment of alzheimer'S disease (AD) with an aluminum salt

AssigneeAffiris AG

InventorsMarkus Mandler, Achim Schneeberger, Frank Mattner, Walter Schmidt

Life of this patent

Estimating the term…

Abstract

Disclosed is a method for the treatment of AD, wherein an immune stimulating pharmaceutical composition comprising an aluminium salt is administered to a patient having AD or having a risk to develop AD in an effective amount.

Claims19

Dependent claims

A method for treating Alzheimer's Disease (AD) comprising administering a single administration dose comprising at least 1.2 mg of an aluminium salt as the effective ingredient to a human patient having AD or having a risk of developing AD.

Dependencies are inferred from the claim text.

Facts

Application: 15/307,714Filed 29 Apr 2015 · us provisional application
Priority: EP 1416635529 Apr 2014
Published: US 2017/0056495 A12 Mar 2017
Granted: 12 May 2020
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 39/39
Medicinal preparations containing antigens or antibodies: characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 33/06
Medicinal preparations containing inorganic active ingredients: aluminium, calcium or magnesium; Compounds thereof , e.g. clay
A61K 33/08
Aluminium, calcium or magnesium; Compounds thereof , e.g. clay: oxides; Hydroxides

Family

Application61/985,710Us provisional application · filed 29 Apr 2014
US 2017/0056495 A1Pre-grant publication · published 2 Mar 2017
US 10,646,565 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results